ATE241385T1 - Rekombinante adenovirus-vakzinen - Google Patents

Rekombinante adenovirus-vakzinen

Info

Publication number
ATE241385T1
ATE241385T1 AT94305656T AT94305656T ATE241385T1 AT E241385 T1 ATE241385 T1 AT E241385T1 AT 94305656 T AT94305656 T AT 94305656T AT 94305656 T AT94305656 T AT 94305656T AT E241385 T1 ATE241385 T1 AT E241385T1
Authority
AT
Austria
Prior art keywords
recombinant adenovirus
cell mediated
mediated immunity
warm blooded
blooded mammal
Prior art date
Application number
AT94305656T
Other languages
English (en)
Inventor
Alan Robert Davis
Paul Porwen Hung
Michael David Lubeck
Robert James Natuk
Pranab Kumar Chanda
Shridhara Chikkatur Sha Murthy
Shaw-Guang Lin Lee
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE241385T1 publication Critical patent/ATE241385T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
AT94305656T 1993-08-11 1994-07-29 Rekombinante adenovirus-vakzinen ATE241385T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10523293A 1993-08-11 1993-08-11
US27628994A 1994-07-20 1994-07-20

Publications (1)

Publication Number Publication Date
ATE241385T1 true ATE241385T1 (de) 2003-06-15

Family

ID=26802374

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94305656T ATE241385T1 (de) 1993-08-11 1994-07-29 Rekombinante adenovirus-vakzinen

Country Status (17)

Country Link
EP (1) EP0638316B1 (de)
JP (1) JPH07145079A (de)
KR (1) KR100347220B1 (de)
AT (1) ATE241385T1 (de)
AU (2) AU6889194A (de)
BR (1) BR9403202A (de)
CA (1) CA2130202A1 (de)
DE (1) DE69432730T2 (de)
DK (1) DK0638316T3 (de)
ES (1) ES2196018T3 (de)
FI (1) FI113621B (de)
HK (1) HK1009934A1 (de)
HU (1) HUT69793A (de)
IL (1) IL110560A (de)
NZ (1) NZ264190A (de)
PT (1) PT638316E (de)
SG (1) SG43029A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
EP2298900A1 (de) * 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und Verfahren zur Behandlung intrazellulärer Erkrankungen
US5849561A (en) * 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
JP2003530307A (ja) 1999-07-06 2003-10-14 メルク・アンド・カンパニー・インコーポレーテッド ｇａｇ遺伝子保有アデノウイルスＨＩＶワクチン
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
CA2467486A1 (en) 2001-11-30 2003-06-12 Isis Innovation Limited Vaccine
BRPI0504782A (pt) 2005-11-01 2007-09-18 Fundacao Oswaldo Cruz adenovìrus recombinantes, processo de construção de adenovìrus recombinantes, composição de vacina contra toxoplasmose, e método de imunização contra infecções causadas pelo parasita t. gondii

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL76751A (en) * 1984-11-01 1991-04-15 American Home Prod Method and oral vaccines against infectious organisms using live,recombinant adenovirus for the production of antibodies
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
ATE163676T1 (de) * 1990-10-17 1998-03-15 Us Health Molekulare klone von hiv-1 und deren verwendung
EP0563323A4 (en) * 1990-12-19 1996-02-28 Epitope Inc Hiv reverse transcriptase vaccine
PT586076E (pt) * 1992-08-07 2003-11-28 Wyeth Corp Vacinas de adenovirus recombinantes

Also Published As

Publication number Publication date
JPH07145079A (ja) 1995-06-06
AU4850697A (en) 1998-03-26
BR9403202A (pt) 1995-04-11
FI943626A0 (fi) 1994-08-04
HK1009934A1 (en) 1999-06-11
SG43029A1 (en) 1997-10-17
FI943626A (fi) 1995-02-12
ES2196018T3 (es) 2003-12-16
DK0638316T3 (da) 2003-09-22
IL110560A (en) 1998-10-30
KR950005326A (ko) 1995-03-20
KR100347220B1 (ko) 2003-02-26
DE69432730T2 (de) 2004-03-25
NZ264190A (en) 1997-06-24
EP0638316A1 (de) 1995-02-15
DE69432730D1 (de) 2003-07-03
EP0638316B1 (de) 2003-05-28
HUT69793A (en) 1995-09-28
CA2130202A1 (en) 1995-02-12
HU9402309D0 (en) 1994-10-28
PT638316E (pt) 2003-10-31
AU6889194A (en) 1995-02-23
FI113621B (fi) 2004-05-31
IL110560A0 (en) 1994-11-11

Similar Documents

Publication Publication Date Title
PT586076E (pt) Vacinas de adenovirus recombinantes
EP0759935A4 (de) Rekombinanter papillomavirus l1
PT101052A (pt) Proteinas hibridas uteis na preparacao de vacinas
ATE241385T1 (de) Rekombinante adenovirus-vakzinen
NZ238833A (en) Equine herpesvirus-4 gh or gc polypeptides, nucleic acids encoding them and vaccines therefrom
DE3585578D1 (de) Hepatitisoberflaechenantigenpartikelvakzin.
AU2403188A (en) Infectious bovine rhinotracheitis virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
DE69433760D1 (de) Gegen mumps impfstoff, das ein virus des jeryl-lynn stammes enthält
DK43991D0 (da) Allele varianter af plasmodium falciparum merozoitoverfladeantigen
GB2244273A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0638316

Country of ref document: EP

REN Ceased due to non-payment of the annual fee